-
2005
Company Description
EyeCyte is engaged in the development of therapeutics for the treatment of neovascular and degenerative retinal diseases.
EyeCyte, Inc. is working with Pfizer's Bioinnovation and iotherapeutics Center and The Scripps Research Institute to develop novel therapeutics to treat neovascular and degenerative retinal disease.
-
Manufacturer:
Science and Engineering -
Formed:
2005 -
Company Website:
-
Company E-mail:
-
Company Address:
3366 North Torrey Pines Court, Suite 130La Jolla, CAUnited States -
CEO:
- Noushin Dunkelman
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits